ArticleIntegrative cancer therapies
Efficacy of Chinese Herbal Medicine in Managing Hot Flushes in Breast Cancer Patients on Adjuvant Chemotherapy: A Clinical Investigation.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChinese herbal medicine (CHM), a commonly used alternative therapy, has been reported to reduce the side effects of cancer treatments and improve the quality of life (QOL) in breast cancer (BC) patients. However, there is limited research on the effects of CHM in BC patients experiencing hot flushes (HFs) during adjuvant chemotherapy. We conducted a non-randomized controlled trial to evaluate the effectiveness of CHM on side effects, QOL, and changes in meridian electrodermal activity.
methodsForty-eight patients with stage I-III BC undergoing adjuvant chemotherapy were non-randomly assigned to either a 24-week CHM treatment group or a 24-week non-CHM control group. The CHM intervention involved a combination of Jia Wei Xiao Yao San and Er Zhi Wan in a 3:1 ratio, with a total daily dose of 4 g taken 3 times a day. The primary outcome was the occurrence of 10 or more HFs per week and the severity of symptoms, rated using a visual analog scale (1-10). Secondary outcomes included the Functional Assessment of Cancer Therapy-Breast Cancer questionnaire to assess health-related QOL, and meridian energy analysis to measure skin electrical conductance and sympathetic activity. The difference between the CHM and non-CHM groups in individual changes from baseline to week 24 was evaluated using an independent
resultsA total of 43 participants completed the study, with 25 in the CHM group and 18 in the control group. The CHM group showed a statistically significant reduction in HF frequency at 12 and 24 weeks and a decrease in HF severity at 12 weeks compared to the control group (
conclusionsCHM therapy appears to have a preventive effect on chemotherapy-related HFs in BC patients and is safe, with no severe adverse effects observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.